Mannatech, Incorporated (NASDAQ: MTEX), the leading innovator and provider of nutritional supplements and skin care products based on Real Food Technology® solutions, announced a new patent grant today. A Notice of Grant of the patent entitled “Compositions of Plant Carbohydrates as Dietary Supplements” was published in the Brazilian Industrial Property Journal on October 18, 2011. This brings the total number of patents related to our Ambrotose® technology to 52. “This latest addition to our large patent portfolio reinforces our leadership position in the dietary supplement industry,” said Robert A. Sinnott, Ph.D., MNS, co-CEO and chief science officer of Mannatech. “As Mannatech continues publishing its research in peer-reviewed scientific journals, this further establishes Mannatech as an unparalleled innovator of scientifically validated nutritional supplements.” Mannatech currently holds more than 70 patents that have been issued worldwide for the technology relating to Ambrotose, Ambrotose AO®, GI-ProBalance® and PhytoMatrix® product formulations. Many of Mannatech's products are based on Real Food Technology solutions, which provide consumers with products that contain standardized levels of natural and plant-sourced nutrients. Food-sourced ingredients are chosen from those scientifically proven to most benefit the human body. Individuals interested in Mannatech’s products or in exploring its business opportunity can learn more at Mannatech.com. http://us.mannatech.com http://www.allaboutmannatech.com/ About Mannatech Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech's proprietary products are available through independent sales Associates around the globe including the United States, United Kingdom, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea and Mexico. For more information, visit Mannatech.com.
Please note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.Investor Relations ContactPhone: 972-471-6512Fax: 972-471-7342